Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 2, 2006 - Issue 1
Submit an article Journal homepage
111
Views
11
CrossRef citations to date
0
Altmetric
Review

Contribution of CYP2C9 to variability in vitamin K antagonist metabolism

Ann K Daly Professor of Pharmacogenetics, University of Newcastle Medical School, School of Clinical and Laboratory Sciences, Framlington Place, Newcastle upon Tyne NE2 4HH, UK. [email protected]
&
Barry P King Research Associate, University of Newcastle Medical School, School of Clinical and Laboratory Sciences, Framlington Place, Newcastle upon Tyne NE2 4HH, UK
Pages 3-15 | Published online: 01 Feb 2006

Bibliography

  • UMBENHAUER DR, MARTIN MV, LLOYD RS, GUENGERICH FP: Cloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P450 S-mephenytoin 4-hydroxylase. Biochemistry (1987) 26:1094-1099.
  • KIMURA S, PASTEWKA J, GELBOINHV, GONZALEZ FJ: cDNA and amino-acid-sequences of 2 members of the human P450IIC gene subfamily. Nucleic Acids Res. (1987) 15(23):10053-10054.
  • YASUMORI T, KAWANO S, NAGATA K, SHIMADA M, YAMAZOE Y, KATO R: Nucleotide sequence of a human liver cytochrome P450 related to the rat male-specific form. J. Biochem. (1987) 102:493-501.
  • MEEHAN RR, GOSDEN JR, ROUT D etal.: Human cytochrome P450 PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10. Am. J. Hum. Genet. (1988) 42:26-37.
  • RETTIE AE, KORZEKWA KR, KUNZEKL etal.: Hydroxylation of warfarin by human cDNA-expressed cytochrome P450 a role for P4502C9 in the etiology of (S)-warfarin drug interactions. Chem. Res. Toxicol. (1992) 5(1):54-59.
  • LEE CR, GOLDSTEIN JA, PIEPER JA: Cytochrome P4502C9 polymorphisms: a comprehensive review of the invitro and human data. Pharmacogenetics (2002) 12(3):251-263.
  • THIJSSEN HH, FLINOIS J-P, BEAUNEPH: Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab. Dispos. (2000) 28:1284-1290.
  • UFER M, SVENSSON JO, KRAUSZ KW, GELBOIN HV, RANE A, TYBRING G: Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation invitro. Eur. J. Clin. Pharmacol. (2004) 60(3):173-182.
  • EVANS WE, RELLING MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 286:487-491.
  • SHIMADA T, YAMAZAKI H, MIMURAM, INUI Y, GUENGERICHFP: Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. (1994) 270:414-423.
  • LAPPLE F, VON RICHTER O, FROMMMF etal.: Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics (2003) 13(9):565-575.
  • DICKINS M: Induction of cytochromes P450. Cur. Top. Med. Chem. (2004) 4(16):1745-1766.
  • KIRCHHEINER J, BROCKMOLLER J: Clinical consequences of cytochrome P4502C9 polymorphisms. Clin. Pharmacol. Ther. (2005) 77(1):1-16.
  • MINERS JO, BIRKETT DJ: Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. (1998) 45(6):525-538.
  • NIEMI M, BACKMAN JT, FROMM MF, NEUVONEN PJ, KIVISTO KT: Pharmacokinetic interactions with rifampicin clinical relevance. Clin. Pharmacokinet. (2003) 42(9):819-850.
  • DEMORAIS SMF, SCHWEIKL H, BLAISDELL J, GOLDSTEIN JA: Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. Biochem. Biophys. Res. Commun. (1993) 194(1):194-201.
  • GED C, BEAUNE P: Isolation of the human cytochrome P450 IIC8 gene multiple glucocorticoid responsive elements in the 5 region. Biochim. Biophys. Acta (1991) 1088(3):433-435.
  • IBEANU GC, GOLDSTEIN JA: Transcriptional regulation of human CYP2C genes functional comparison of CYP2C9 and CYP2C18 promoter regions. Biochemistry (1995) 34(25):8028-8036.
  • GERBAL-CHALOIN S, DAUJAT M, PASCUSSI JM, PICHARD-GARCIA L, VILAREM MJ, MAUREL P: Transcriptional regulation of CYP2C9 gene role of glucocorticoid receptor and constitutive androstane receptor. J. Biol. Chem. (2002) 277(1):209-217.
  • HAINING RL, JONES JP, HENNE KR etal.: Enzymatic determinants of the substrate specificity of CYP2C9: role of BC loop residues in providing the -stacking anchor site for warfarin binding. Biochemistry (1999) 38(11):3285-3292.
  • MELET A, ASSRIR N, JEAN P etal.: Substrate selectivity of human cytochrome P4502C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid. Arch. Biochem. Biophys. (2003) 409(1):80-91.
  • WILLIAMS PA, COSME J, WARD A, ANGOVA HC, VINKOVIC DM, JHOTIH: Crystal structure of human cytochrome P4502C9 with bound warfarin. Nature (2003) 424(6947):464-468.
  • WESTER MR, YANO JK, SCHOCH GA etal.: The structure of human cytochrome P4502C9 complexed with flurbiprofen at 2.0-angstrom resolution. J. Biol. Chem. (2004) 279(34):35630-35637.
  • HUTZLER JM, HAUER MJ, TRACY TS: Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. Drug Metab. Dispos. (2001) 29(7):1029-1034.
  • FURUYA H, FERNANDEZSALGUEROP, GREGORYW etal.: Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics (1995) 5(6):389-392.
  • WANG S-L, HUANG J-D, LAI M-D, TSAI J-J: Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics (1995) 5:37-42.
  • STUBBINS MJ, HARRIES LW, SMITHG, TARBIT MH, WOLF CR: Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics (1996) 6(5):429-439.
  • SULLIVAN TH, GHANAYEM BI, BELLDA etal.: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics (1996) 6:341-349.
  • XIE H-G, PRASAD HC, KIM RB, STEINCM: CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev. (2002) 54:1257-1270.
  • CRESPI CL, MILLER VP: The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics (1997) 7(3):203-210.
  • HAINING RL, HUNTER AP, VERONESE ME, TRAGER WF, RETTIEAE: Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch. Biochem. Biophys. (1996) 333(2):447-458.
  • KIDD RS, CURRY TB, GALLAGHER S, EDEKI T, BLAISDELL J, GOLDSTEINJA: Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics (2001) 11(9):803-808.
  • GOTOH O: Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J. Biol. Chem. (1992) 267:83-90.
  • SHINTANI M, IEIRI I, INOUE K etal.: Genetic polymorphisms and functional characterization of the 5-flanking region of the human CYP2C9 gene: invitro and invivo studies. Clin. Pharmacol. Ther. (2001) 70(2):175-182.
  • TAKAHASHI H, IEIRI I, WILKINSONGR etal.: 5-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in Caucasian and Japanese patients. Blood (2004) 103:3055-3057.
  • KING BP, KHAN TI, AITHAL GP, KAMALI F, DALY AK: Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics (2004) 14(12):813-822.
  • VEENSTRA DL, BLOUGH DK, HIGASHI MK etal.: CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin. Pharmacol. Ther. (2005) 77(5):353-364.
  • DELOZIER TC, LEE SC, COULTER SJ, GOH BC, GOLDSTEIN JA: Functional characterization of novel allelic variants of CYP2C9 recently discovered in Southeast Asians. J. Pharmacol. Exp. Ther. (2005) (InPress).
  • TAI G, FARIN F, RIEDER MJ etal.: Invitro and invivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenet. Genomics (2005) 15(7):475-481.
  • LEUNG AYH, CHOW HCH, KWONGYL etal.: Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood (2001) 98(8):2584-2587.
  • RETTIE AE, TAI GY, VEENSTRA DL etal.: CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians. Blood (2003) 101(7):2896-2897.
  • KAMINSKY LS, ZHANG ZY: Human P450 metabolism of warfarin. Pharmacol. Ther. (1997) 73(1):67-74.
  • YAMAZAKI H, SHIMADA T: Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Biochem. Pharmacol. (1997) 54(11):1195-1203.
  • STEWARD DJ, HAINING RL, HENNEKR etal.: Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics (1997) 7(5):361-367.
  • AITHAL GP, DAY CP, KESTEVEN PJL, DALY AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet (1999) 353(9154):717-719.
  • HIGASHI MK, VEENSTRA DL, KONDO LML etal.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 287(13):1690-1698.
  • SANDERSON S, EMERY J, HIGGINS J: CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet (TM) systematic review and meta-analysis. Genet. Med. (2005) 7(2):97-104.
  • TAUBE J, HALSALL D, BAGLIN T: Influence of cytochrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood (2000) 96(5):1816-1819.
  • GAGE BF, EBY C, MILLIGAN PE, BANET GA, DUNCAN JR, MCLEODHL: Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb. Haemost. (2004) 91(1):87-94.
  • KAMALI F, KHAN TI, KING BP etal.: Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin. Pharmacol. Ther. (2004) 75(3):204-212.
  • HILLMAN MA, WILKE RA, CALDWELL MD, BERG RL, GLURICHI, BURMESTER JK: Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics (2004) 14(8):539-547.
  • TAKAHASHI H, KASHIMA T, NOMOTO S etal.: Comparisons between invitro and invivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics (1998) 8(5):365-373.
  • LOEBSTEIN R, YONATH H, PELEG D etal.: Interindividual variability in sensitivity to warfarin nature or nurture? Clin. Pharmacol. Ther. (2001) 70(2):159-164.
  • SCORDO MG, PENGO V, SPINA E, DAHL ML, GUSELLA M, PADRINI R: Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Pharmacol. Ther. (2002) 72:702-710.
  • LINDER MW, LOONEY S, ADAMSJE3rd etal.: Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J. Thromb. Thrombolysis (2002) 14(3):227-232.
  • TAKAHASHI H, ECHIZEN H: Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet. (2001) 40(8):587-603.
  • VOORA D, EBY C, LINDER MW etal.: Prospective dosing of warfarin based on cytochrome P4502C9 genotype. Thromb. Haemost. (2005) 93(4):700-705.
  • THIJSSEN HHW, VERKOOIJEN IWC, FRANK HLL: The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol. Pharmacogenetics (2000) 10(8):757-760.
  • VERSTUYFT C, MORIN S, ROBERT A etal.: Early acenocoumarol overanticoagulation among cytochrome P4502C9 poor metabolizers. Pharmacogenetics (2001) 11(8):735-737.
  • HERMIDA J, ZARZA J, ALBERCA I etal.: Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P450CYP2C9 on sensitivity to acenocournarol. Blood (2002) 99(11):4237-4239.
  • TASSIES D, FREIRE C, PUOAN J etal.: Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica (2002) 87(11):1185-1191.
  • SCHALEKAMP T, OOSTERHOF M, VAN MEEGEN E etal.: Effects of cytochrome P4502C9 polymorphisms on phenprocoumon anticoagulation status. Clin. Pharmacol. Ther. (2004) 76(5):409-417.
  • MORIN S, BODIN L, LORIOT MA etal.: Pharmacogenetics of acenocoumarol pharmacodynamics. Clin. Pharmacol. Ther. (2004) 75(5):403-414.
  • VISSER LE, VAN VLIET M, VANSCHAIK RHN etal.: The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics (2004) 14(1):27-33.
  • KIRCHHEINER J, UFER M, WALTEREC etal.: Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. Pharmacogenetics (2004) 14(1):19-26.
  • UFER M: Effects of CYP2C9 polymorphisms on phenprocoumon anticoagulation status. Clin. Pharmacol. Ther. (2005) 77(4):335-336.
  • ROST S, FREGIN A, IVASKEVICIUS V etal.: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature (2004) 427(6974):537-541.
  • LI T, CHANG CY, JIN DY, LIN PJ, KHVOROVA A, STAFFORD DW: Identification of the gene for vitamin K epoxide reductase. Nature (2004) 427(6974):541-544.
  • DANDREA G, DAMBROSIO RL, DIPERNA P etal.: A polymorphism in VKORC1 gene is associated with an inter-individual variability in the dose-anticoagulant effect of warfarin. Blood (2005) 105(2):645-649.
  • BODIN L, VERSTUYFT C, TREGOUETDA etal.: Cytochrome P4502C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood (2005) 106(1):135-140.
  • RIEDER MJ, REINER AP, GAGE BF etal.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. (2005) 352(22):2285-2293.
  • SCONCE EA, KHAN TI, WYNNE HA etal.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood (2005) 106:2329-2333.
  • YUAN HY, CHEN JJ, LEE MTM etal.: A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. (2005) 14(13):1745-1751.
  • WADELIUS M, CHEN LY, DOWNES K etal.: Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. (2005) 5(4):262-270.
  • HALLAK HO, WEDLUND PJ, MODIMW etal.: High clearance of (S)-warfarin in a warfarin-resistant subject. Br. J. Clin. Pharmacol. (1993) 35:327-330.
  • IEIRI I, TAINAKA H, MORITA T etal.: Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. Ther. Drug Monit. (2000) 22(3):237-244.
  • DICKMANN LJ, RETTIE AE, KNELLERMB etal.: Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African-Americans. Mol. Pharmacol. (2001) 60(2):382-387.
  • BLAISDELL J, JORGE-NEBERT LF, COULTER S etal.: Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics (2004) 14(8):527-537.
  • SI DY, GUO YJ, ZHANG YF, YANG L, ZHOU H, ZHONG DF: Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics (2004) 14(7):465-469.
  • ZHAO F, LOKE C, RANKIN SC etal.: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin. Pharmacol. Ther. (2004) 76(3):210-219.
  • OGG MS, BRENNAN P, MEADE T, HUMPHRIES SE: CYP2C9*3 allelic variant and bleeding complications. Lancet (1999) 354(9184):1124.
  • MARGAGLIONE M, COLAIZZO D, DANDREA G etal.: Genetic modulation of oral anticoagulation with warfarin. Thromb. Haemost. (2000) 84(5):775-778.
  • TABRIZI AR, ZEHNBAUER BA, BORECKI IB, MCGRATH SD, BUCHMAN TG, FREEMAN BD: The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J. Am. Coll. Surg. (2002) 194(3):267-273.
  • LEE S, KIM JM, CHUNG CS, CHO KJ, KIM JH: Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients. Arch. Pharmacol. Res. (2003) 26(11):967-972.
  • WADELIUS M, SORLIN K, WALLERMAN O etal.: Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J. (2004) 4(1):40-48.
  • PEYVANDI F, SPREAFICO M, SIBONISM, MOIA M, MANNUCCIPM: CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin. Pharmacol. Ther. (2004) 75(3):198-203.
  • REDMAN AR, DICKMANN LJ, KIDDRS, GOLDSTEIN JA, RITCHIEDM, HON YY: CYP2C9 genetic polymorphisms and warfarin. Clin. App. Thromb.-Hemost. (2004) 10(2):149-154.
  • SHIKATA E, IEIRI I, ISHIGURO S etal.: Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and -glutamyl carboxylase) gene variants with warfarin sensitivity. Blood (2004) 103(7):2630-2635.
  • JOFFE HV, XU RL, JOHNSON FB, LONGTINE J, KUCHER N, GOLDHABER SZ: Warfarin dosing and cytochrome P4502C9 polymorphisms. Thromb. Haemost. (2004) 91(6):1123-1128.
  • PCHELINA SN, SIROTKINA OV, TARASKINA AE, VAVILOVA TV, SHWARZMAN AL, SCHWARTZ EI: The frequency of cytochrome P450 2C9 genetic variants in the Russian population and their associations with individual sensitivity to warfarin therapy. Thromb. Res. (2005) 115(3):199-203.
  • HERMAN D, LOCATELLI I, GRABNARI etal.: Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J. (2005) 5(3):193-202.
  • PALARETI G, LEGNANI C, GUAZZALOCA G etal.: Risks factors for highly unstable response to oral anticoagulation: a case-control study. Br. J. Haematol. (2005) 129(1):72-78.
  • HILLMAN MA, WILKE RA, YALE SH etal.: A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin. Med. Res. (2005) 3(3):137-145.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.